Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients With Advanced BRCA1- or BRCA2-associated Breast Cancer.

NCT00494234 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00494234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00494234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients With Advanced BRCA1- or BRCA2-associated Breast Cancer.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2007
Completion date
December 21, 2022
Enrollment
54 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms